Ophthalmic Advisory Committee To Consider Two New Fields For Drug Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech's Lucentis (ranibizumab) for diabetic macular edema and ThromboGenics's Jetrea (ocriplasmin intravitreal injection) for symptomatic vitreomacular adhesions would both be the first pharmacologic intervention for those indications, replacing surgical standards of care.